President & CEO, Co-Founder
Carol Burns is a serial entrepreneur with extensive experience in the cardiovascular sector. She is the founding CEO of Cagent Vascular. Previously she served as the founding CEO of Intact Vascular, the first company formed with her partners Robert Giasolli and Peter Schneider, MD. She has proven success raising capital, recruiting high performance management teams and achieving milestones in a capital efficient manner. Ms. Burns was an integral team member in Embrella Cardiovascular (sold to Edwards LifeScience’s), Animas Corporation (acquired by Johnson & Johnson), Ventrica (acquired by Medtronic) and Guidant Corporation. Carol is a registered nurse, bringing in-depth, clinical expertise to Cagent Vascular. Ms. Burns serves on the Penn Health-Tech Strategic Advisory Board.
VP Clinical Engineering & Chief Technology Officer, Co-Founder
Robert Giasolli is a co-founder of Cagent Vascular and previous co-founder of Intact Vascular. Currently he serves as the Chief Technology Officer and Vice President of Research and Development. He is a leading innovator and inventor of medical device technologies including the Tack Endovascular System® (Intact Vascular) and the Serranator® PTA Serration Balloon Catheter (Cagent Vascular). His years of experience in developing new technologies has enabled him to create Cagent Vascular’s strong patent portfolio. He is published in the medical and micro-technology fields with multiple peer reviewed publications and over 100 issued patents.
VP Finance & Business Operations
Aaron Green is a seasoned medical device executive with deep experience both domestically and internationally. Early in his career, he worked in financial services and private equity turnaround and transitioned to healthcare having worked at Medtronic and Samsung Medical. He has vast experience in various business operations roles including leading new product and service launches, executing marketing strategies including pricing and reimbursement positioning, and developing robust supply chain pipelines. Aaron has also worked extensively with Hospitals, ASCs, and OBLs to provide them with value-based care solutions for their evolving practice needs.
Peter Johansson, PE
Chief Quality & Compliance Officer,
Peter Johansson is a proud Air Force Veteran who possesses nearly 30 years of medical device development and engineering experience in the cardiac and peripheral vascular space. He has led teams of engineers from early stage design and development through regulatory approval and commercialization. His contributions have been extremely valuable, resulting in seven of the companies having been acquired. Over the course of his career, Peter has worked on pioneering first-in-class products, including the first endovascular AAA device, large bore access closure, and early structural heart devices. He has authored a best-practices quality management system that has been implemented at Cagent Vascular.
VP Operations & Contract Manufacturing
Lourdes Ruiz is a seasoned business veteran with over 30 years of experience in medical devices from highly recognized companies including Johnson & Johnson and Danaher. She has expertise in managing all aspects of Global Operations, Supply Chain, and Quality Assurance. As a Lean and 6-Sigma Black Belt, she has led strategic initiatives for supply chain and operational excellence and delivered transformational results both domestically and internationally. These experiences have proved to be extremely valuable in her role overseeing Product Development, Supply Chain, Manufacturing and Project Management.
Peter Schneider, MD
Chief Medical Officer, Co-Founder
Dr. Schneider is an innovator, serial entrepreneur, and pioneer in the endovascular interventions space and is the co-founder of Cagent Vascular and Intact Vascular. He is a Board Certified Vascular Surgeon practicing at the University of California San Francisco. Dr. Schneider is the author of the widely used, seminal medical textbook Endovascular Skills. He is also a prolific researcher with multiple scientific publications and advisory board positions for companies including Abbott, Boston Scientific, and Medtronic. He is highly sought after as a Principal Investigator for new, emerging technologies. Dr. Schneider has previously served as the president of VIVA.